Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Cancer Advances

Cancer Advances?uq=oeHSfu7P
2008 FOUNDED
PRIVATE STATUS
Platform LATEST DEAL TYPE
1 INVESTORS
Description

Developer of a therapeutic product designed to treat gastrointestinal cancers. The company's therapeutic products, Polyclonal Antibody Stimulator, a fusion peptide, enables treatment of gastrointestinal cancers, metastatic gastrinoma, and benign colorectal adenoma.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Westpark Corporate Center
  • 4364 South Alston Avenue, Suite 210
  • Durham, NC 27713
  • United States

+1 (919) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Cancer Advances’s full profile, request a free trial.

Cancer Advances Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Platform Creation Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Cancer Advances Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cato BioVentures Corporate Venture Capital Majority 000 0000 000000 0

Cancer Advances Executive Team (3)

Name Title Board
Seat
Contact
Info
Allen Cato Ph.D Senior Vice President of Drug Development
Allen Cato MD Chief Executive Officer & Chief Medical Officer
Lynda Sutton President